Phase I dose escalation study of lestaurtinib in patients with myelofibrosis

Despite extensive prior clinical investigation in acute leukemia (60 – 100 mg), dose finding studies have not yet established a true maximum tolerated dose (MTD) for the oral multi-kinase inhibitor lestaurtinib in hematologic malignancies. We performed a multicenter, investigator initiated, phase I...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Leuk Lymphoma
Main Authors: Hexner, Elizabeth O, Mascarenhas J, John, Prchal, Josef, Roboz, Gail J, Baer, Maria R, Ritchie, Ellen K, Leibowitz, David, Demakos, Erin P, Miller, Crystal, Siuty, James, Kleczko, Jill, Price, Leah, Jeschke, Grace, Weinberg, Rona, Basu T, Titiksha, Pahl, Heike L, Orazi, Attilio, Najfeld, Vesna, Marchioli, Roberto, Goldberg, Judith D, Silverman, Lewis R, Hoffman, Ronald
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5665563/
https://ncbi.nlm.nih.gov/pubmed/25563429
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2014.1001986
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados